Sanyou Biopharmaceuticals, a Shanghai-based biopharmaceutical company specializing in biologics R&D, signed a strategic cooperation agreement with Medicovestor, Inc., a New York-based biotech company developing first-in-class chemoimmunotherapy antibody-drug conjugates (ADCs).

The agreement combines Medicovestor’s ADC platforms—ADoBind, a dimeric antibody architecture, and ADoTope, a bi-epitope targeting system—with Sanyou’s AI-STAL (Artificial Intelligence-enabled Super Trillion Antibody Library) technology and intelligent drug screening and preclinical research capabilities. The collaboration aims to accelerate the development of first-in-class chemoimmunotherapies for oncology and autoimmune diseases.

Medicovestor has two technology platforms that enable higher efficacy at lower doses and support combination therapies. Its lead program has entered the IND-enabling stage, with a pancreatic cancer therapy submitted for FDA Orphan Drug Designation.  

The partnership includes joint research, technology transfer, and co-development of lead candidates. Both companies plan to announce development milestones and candidate selections in the coming quarters.

“This partnership reflects our commitment to redefining ADCs by integrating our differentiated ADC platforms with Sanyou’s world-class expertise in antibody development to incorporate immunotherapy into ADCs,” said Seah Lim, MD, PhD, Founder and CEO of Medicovestor. “Together, our complementary strengths create a powerful engine to unlock novel therapeutic possibilities for patients with limited treatment options.”

“We are excited to collaborate with Medicovestor to realize the promise of their highly innovative chemoimmunotherapy ADC platforms,” said David Lang, PhD, Founder and CEO of Sanyou Biopharmaceuticals. “By combining scientific excellence with execution capability, we aim to deliver transformative therapies that change patients’ lives.”